OpGen, Curetis, and Ares Genetics have combined their businesses to build stronger diagnostic solutions for severe infections. Read more.

Rapid and comprehensive

molecular diagnostic infectious disease panels, including detection of bacterial co-infections in COVID-19 pneumonia.

A new light on antibiotic resistance

Using the power of genomics and informatics to fight antibiotic-resistant microbes

Optimizing Genomic Testing for Antibiotic Resistance

Existing tests can take days to identify the correct treatment for a patient’s infection. That’s why caregivers often use broad-spectrum antibiotics as a first defense—but when those drugs are overused, antibiotic-resistant microbes can emerge. OpGen is developing a better way to treat infection while preventing antibiotic resistance. We harness the power of informatics and genomics to identify antimicrobial resistant (AMR) organisms quickly and accurately, with an aim to improve treatment at the patient, hospital, and network level.


Deaths each year from bacterial infections (WHO)


Deaths annually in the us & europe from drug-resistant infections

$20 billion

Excess direct healthcare costs in the us from drug-resistant infections

Oliver Schacht Video


CEO Oliver Schacht discusses the new OpGen

Watch Now

Digital Trends logo

In The News

COVID-19 patients at risk for bacterial pneumonia co-infection.

Learn More

antimicrobial agents


OpGen accurately and reliably predicts antibiotic resistance in comprehensive study

Read More

Latest News

  • 6.9.21
    OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed  MORE
  • 6.9.21
    OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars  MORE
  • 6.7.21
    OpGen Submits Updated 510(k) Summary to FDA and Successfully Completes Move to New Headquarters in Maryland  MORE

See all news

Upcoming Events

    There are currently no upcoming events.

    See all events

    Latest Blog Posts

    • 3.08.21
      The Unyvero Hospital-Acquired pneumonia panel for diagnosis of secondary bacterial pneumonia in COVID-19 patients  MORE
    • 3.08.21
      Multicenter Evaluation of the Unyvero Platform for Testing Bronchoalveolar Lavage Fluid  MORE
    • 10.01.20
      Performance Evaluation of Multiplex-PCR Pneumonia Panel for Diagnosis of Bacterial Co-Infections Among COVID-19 Patients  MORE

    See blog

    Contact Us

    For more information on our products and services:
    • This field is for validation purposes and should be left unchanged.